» Articles » PMID: 27774920

Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study

Overview
Specialty Neurology
Date 2016 Oct 25
PMID 27774920
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pathophysiological mechanisms that contribute to neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) include oxidative stress and inflammation. We conducted a preliminary study to explore these mechanisms, to discuss their link in ALS, and to determine the feasibility of incorporating this combined analysis into current biomarkers research.

Methods: We enrolled 10 ALS patients and 10 controls. We measured the activities of glutathione peroxidase, glutathione reductase, superoxyde dismutase (SOD), and the levels of serum total antioxidant status (TAS), malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and glutathione status (e.g. glutathione disulfide, GSSG/reduced glutathione, GSH). We analysed the concentrations of homocysteine, several cytokines, vitamins and metals by standard methods used in routine practice.

Results: There was a significant decrease in TAS levels (p=0.027) and increase in 8-OHdG (p=0.014) and MDA (p=0.011) levels in ALS patients. We also observed a significantly higher GSSG/GSH ratio (p=0.022), and IL-6 (p=0.0079) and IL-8 (p=0.009) concentrations in ALS patients. Correlations were found between biological and clinical markers (homosysteine vs. clinical status at diagnosis, p=0.02) and between some biological markers such as IL-6 vs. GSSG/GSH (p=0.045) or SOD activity (p=0.017).

Conclusion: We confirmed the systemic alteration of both the redox and the inflammation status in ALS patients, and we observed a link with some clinical parameters. These promising results encourage us to pursue this study with collection of combined oxidative stress and inflammatory markers.

Citing Articles

Novel Cell Models to Study Myelin and Microglia Interactions.

Santacreu-Vilaseca M, Moreno-Magallon J, Juanes-Casado A, Gil-Sanchez A, Gonzalez-Mingot C, Torres P Int J Mol Sci. 2025; 26(5).

PMID: 40076804 PMC: 11900003. DOI: 10.3390/ijms26052179.


An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis.

van Eijk R, Steyn F, Janse van Mantgem M, Schmidt A, Meyjes M, Allen S Brain Commun. 2025; 7(1):fcaf063.

PMID: 40008327 PMC: 11851067. DOI: 10.1093/braincomms/fcaf063.


Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications.

Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler J, Hansen S Front Pharmacol. 2024; 15:1437939.

PMID: 39119604 PMC: 11306042. DOI: 10.3389/fphar.2024.1437939.


Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations.

Rogers M, Schultz D, Karnaros V, Shepheard S Brain Commun. 2023; 5(6):fcad287.

PMID: 37946793 PMC: 10631861. DOI: 10.1093/braincomms/fcad287.


Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study.

Carrera-Julia S, Estrela J, Zacares M, Navarro M, Vega-Bello M, de la Rubia Orti J Front Nutr. 2023; 10:1232184.

PMID: 37810917 PMC: 10556480. DOI: 10.3389/fnut.2023.1232184.